header
Image from OpenLibrary

Estimation of stem cell frequency in acute myeloid leukemia at diagnosis : Relation to hematological and clinical parameters / Marwa Hanafy Moustafa ; Supervised Azza Mahmoud Kamel , Nahla Mohamed Elsharkawy , Mohamed Abdelmoeti Samra

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Marwa Hanafy Moustafa , 2015Description: 179 P. : charts , facsimiles ; 25cmOther title:
  • قْياس معدل الخلاية الجذعية فى سرطان الدم الميلودى الحاد : ارتباطه بالعوامل الدموية و الاكلينيكية [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Clinical Pathology Summary: Acute myeloid leukemia (AML) is a heterogeneous disorder with treatment results much inferior to acute lymphoblastic leukemia. Treatment failure is largely attributed to the persistence of leukemia stem cells (LSCs) which are less accessible and hence less responsive to chemo-therapeutics. The classical LSCs phenotype is CD34 + / CD38-; however LSCs express other markers especially CD123 and CD133 which may be even earlier than CD34. We hypothesized that that CD123 and CD133 may be better markers of LSCs and that the more the number of LSCs at diagnosis /and or at follow up periods, the more the case would be resistant to therapy. The purpose of this study was to test the efficiency of various antibodies separately or in combinations to characterize LSCs and, if possible, to discriminate them from normal hematopoietic stem cells (HSCs). We aimed thereafter to demonstrate the impact of LSCs frequency at diagnosis and at follow up periods as compared to minimal residual disease (MRD) on overall survival (OS), disease free survival (DFS). We aimed lastly to study the relationship between MRD and LSCs frequency at follow up periods to verify which will be better correlated to outcome
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.19.03.Ph.D.2015.Ma.E (Browse shelf(Opens below)) Not for loan 01010110067475000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.19.03.Ph.D.2015.Ma.E (Browse shelf(Opens below)) 67475.CD Not for loan 01020110067475000

Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Clinical Pathology

Acute myeloid leukemia (AML) is a heterogeneous disorder with treatment results much inferior to acute lymphoblastic leukemia. Treatment failure is largely attributed to the persistence of leukemia stem cells (LSCs) which are less accessible and hence less responsive to chemo-therapeutics. The classical LSCs phenotype is CD34 + / CD38-; however LSCs express other markers especially CD123 and CD133 which may be even earlier than CD34. We hypothesized that that CD123 and CD133 may be better markers of LSCs and that the more the number of LSCs at diagnosis /and or at follow up periods, the more the case would be resistant to therapy. The purpose of this study was to test the efficiency of various antibodies separately or in combinations to characterize LSCs and, if possible, to discriminate them from normal hematopoietic stem cells (HSCs). We aimed thereafter to demonstrate the impact of LSCs frequency at diagnosis and at follow up periods as compared to minimal residual disease (MRD) on overall survival (OS), disease free survival (DFS). We aimed lastly to study the relationship between MRD and LSCs frequency at follow up periods to verify which will be better correlated to outcome

Issued also as CD

There are no comments on this title.

to post a comment.